Effects of PPARgamma-inactive Delta-2-TGZ on breast cancer cells MCF-7. Homo sapiens

TGZ is an agonist of the nuclear receptor PPARgamma. This synthetic compound displays anticancer effects on breast cancer cells but some of them are PPARgamma independent. Delta-2-TGZ (delta-2-troglotazone) is a PPARgamma inactive TGZ derivative possessing a double bond adjoining the thiazolidinedione ring. This compound still displays anticancer efefcts. It is an interesting tool to study the PPARgamma-independent mechanisms. We used microarrays to examine the global programme of gene expression in response to Delta-2-TGZ treatment in MCF7 cell line. Overall design: We compare global gene expression levels between untreated and delta-2-troglitazone treated MCF7 cells at 12H. Each data point was realized in triplicate